HRP20110250T1 - Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze - Google Patents

Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze Download PDF

Info

Publication number
HRP20110250T1
HRP20110250T1 HR20110250T HRP20110250T HRP20110250T1 HR P20110250 T1 HRP20110250 T1 HR P20110250T1 HR 20110250 T HR20110250 T HR 20110250T HR P20110250 T HRP20110250 T HR P20110250T HR P20110250 T1 HRP20110250 T1 HR P20110250T1
Authority
HR
Croatia
Prior art keywords
imatinib
leukemia
cmin
mono
treatment
Prior art date
Application number
HR20110250T
Other languages
English (en)
Croatian (hr)
Inventor
Gathmann Insa
Mahon Francois-Xavier
Molimard Mathieu
Picard St�phane
Wang Yanfeng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110250(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20110250T1 publication Critical patent/HRP20110250T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20110250T 2006-09-22 2007-09-20 Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze HRP20110250T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82662206P 2006-09-22 2006-09-22
US82827806P 2006-10-05 2006-10-05
PCT/US2007/078978 WO2008036792A2 (fr) 2006-09-22 2007-09-20 Procédé d'optimisation de traitement de la leucémie philadelphie positive avec des inhibiteurs de tyrosine kinase abl

Publications (1)

Publication Number Publication Date
HRP20110250T1 true HRP20110250T1 (hr) 2011-05-31

Family

ID=39092883

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110250T HRP20110250T1 (hr) 2006-09-22 2007-09-20 Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze

Country Status (24)

Country Link
US (2) US20090281113A1 (fr)
EP (2) EP2068938B1 (fr)
JP (1) JP5735742B2 (fr)
KR (1) KR20090065512A (fr)
AT (1) ATE495761T1 (fr)
AU (1) AU2007299764B2 (fr)
BR (1) BRPI0717099A2 (fr)
CA (1) CA2662977A1 (fr)
CL (1) CL2007002725A1 (fr)
CY (1) CY1111356T1 (fr)
DE (1) DE602007012122D1 (fr)
DK (1) DK2068938T3 (fr)
HR (1) HRP20110250T1 (fr)
IL (1) IL197296A (fr)
MA (1) MA30786B1 (fr)
MX (1) MX2009003082A (fr)
NO (1) NO20091490L (fr)
NZ (1) NZ575113A (fr)
PL (1) PL2068938T3 (fr)
PT (1) PT2068938E (fr)
TN (1) TN2009000094A1 (fr)
TW (1) TWI398251B (fr)
WO (1) WO2008036792A2 (fr)
ZA (1) ZA200901220B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101951910B (zh) * 2008-01-23 2013-07-17 诺瓦提斯公司 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途
US8697702B2 (en) 2008-12-01 2014-04-15 Novartis Ag Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
US20110046919A1 (en) * 2009-03-02 2011-02-24 Juliesta Elaine Sylvester Method for accurate measurement of enzyme activities
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
JPWO2015076213A1 (ja) * 2013-11-22 2017-03-16 国立研究開発法人国立成育医療研究センター 急性リンパ芽球性白血病の新規キメラ遺伝子ａｔｆ７ｉｐ−ｐｄｇｆｒｂ
CA2991195C (fr) 2015-07-07 2021-06-29 Codexis, Inc. Nouveaux variants de p450-bm3 ayant une activite amelioree
IT201900008808A1 (it) 2019-06-13 2020-12-13 Univ Ca Foscari Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) * 2022-06-28 2022-09-02 北京赛诺浦生物技术有限公司 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
PL215901B1 (pl) 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
WO2003087404A1 (fr) * 2002-04-17 2003-10-23 Novartis Ag Procedes permettant de prevoir la faculte de reponse de patients a des inhibiteurs de tyrosine kinase
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
MA30786B1 (fr) 2009-10-01
NO20091490L (no) 2009-06-15
BRPI0717099A2 (pt) 2013-10-15
PL2068938T3 (pl) 2011-06-30
TW200822926A (en) 2008-06-01
MX2009003082A (es) 2009-04-01
PT2068938E (pt) 2011-03-23
CL2007002725A1 (es) 2008-05-16
CY1111356T1 (el) 2015-08-05
KR20090065512A (ko) 2009-06-22
DK2068938T3 (da) 2011-04-04
WO2008036792A3 (fr) 2008-11-13
HK1133194A1 (en) 2010-03-19
IL197296A0 (en) 2011-08-01
EP2068938B1 (fr) 2011-01-19
IL197296A (en) 2011-11-30
EP2251042A3 (fr) 2012-05-02
EP2251042A2 (fr) 2010-11-17
JP2010504353A (ja) 2010-02-12
AU2007299764A1 (en) 2008-03-27
WO2008036792A2 (fr) 2008-03-27
DE602007012122D1 (de) 2011-03-03
TWI398251B (zh) 2013-06-11
ATE495761T1 (de) 2011-02-15
JP5735742B2 (ja) 2015-06-17
EP2068938A2 (fr) 2009-06-17
CA2662977A1 (fr) 2008-03-27
AU2007299764B2 (en) 2011-10-13
US20090281113A1 (en) 2009-11-12
NZ575113A (en) 2012-03-30
ZA200901220B (en) 2010-02-24
US20170007605A1 (en) 2017-01-12
TN2009000094A1 (en) 2010-08-19
RU2009114856A (ru) 2010-10-27

Similar Documents

Publication Publication Date Title
HRP20110250T1 (hr) Optimalizacija liječenja philadelphia-pozitivne leukemije s imatinibom inhibitorom abl-tirozin kinaze
RU2009127351A (ru) Комбинации антифолатного агента в лечении рака
TWI688387B (zh) 二氫槲皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
GB0423653D0 (en) Pharmaceutical compounds
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
EP2216024A3 (fr) Utilisation de ranolazine pour le traitement de maladies cardiovasculaires
MX2009005398A (es) Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
JP2010503695A5 (fr)
BRPI0810641A2 (pt) "compostos farmacêuticos".
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
WO2014018563A2 (fr) Procédés pour le traitement du cancer
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
RU2008117432A (ru) Способы применения 3-(4-амино-1-оксо-1,3-дигидроизоиндол-2-ил)пиперидин-2,6-диона для лечения определенных типов лейкоза
EA200400982A1 (ru) Способы лечения пациентов, страдающих от нарушения движений
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
RU2017134443A (ru) Способ лечения с применением традипитанта
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
EP4442321A3 (fr) Méthodes de traitement du syndrome de sjögren utilisant un inhibiteur de la kinase de bruton
US20060293309A1 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
MY209220A (en) Dosing regimen for the treatment of pi3k related disorders
WO2004034962A3 (fr) Methode d'utilisation de medicaments selectifs inhibiteurs des cytokines et compositions comprenant des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge de syndromes myelodysplasiques
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t